MRUS | tickerfilter.com

Fundamental analysis

22%

Profitability 25%

Dept financing 14%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

-6.51%

6 Months

33.95%

1 Year

95.23%

2 Year

84.73%

Key data

Stock price

$90.00

P/E Ratio

0.00

DAY RANGE

$87.14 - $96.86

EPS

-$5.38

52 WEEK RANGE

$33.19 - $97.14

52 WEEK CHANGE

$95.35

MARKET CAP

7.121 B

YIELD

N/A

SHARES OUTSTANDING

75.845 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-31-2025

BETA

0.99

PUBLIC FLOAT

AVERAGE 10 VOLUME

N/A

AVERAGE 30 VOLUME

N/A

Company detail

CEO: Sven A. Lundberg
Region: US
Website: merus.nl
Employees: 37
IPO year: 2016

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Merus N.V. engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials. The company is also developing MCLA-158,158,145, and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.

MRUS - Merus N.V.